JP2022501371A - ステロールの精製 - Google Patents

ステロールの精製 Download PDF

Info

Publication number
JP2022501371A
JP2022501371A JP2021515509A JP2021515509A JP2022501371A JP 2022501371 A JP2022501371 A JP 2022501371A JP 2021515509 A JP2021515509 A JP 2021515509A JP 2021515509 A JP2021515509 A JP 2021515509A JP 2022501371 A JP2022501371 A JP 2022501371A
Authority
JP
Japan
Prior art keywords
ester
optionally substituted
lipid
composition
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021515509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501371A5 (https=
Inventor
ブトラ、ガボール
リム、ジン
シェン、ゲイリー
ボルカート、アリソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Publication of JP2022501371A publication Critical patent/JP2022501371A/ja
Publication of JP2022501371A5 publication Critical patent/JP2022501371A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Otolaryngology (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021515509A 2018-09-19 2019-09-19 ステロールの精製 Ceased JP2022501371A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862733522P 2018-09-19 2018-09-19
US62/733,522 2018-09-19
PCT/US2019/051940 WO2020061317A1 (en) 2018-09-19 2019-09-19 Sterol purification

Publications (2)

Publication Number Publication Date
JP2022501371A true JP2022501371A (ja) 2022-01-06
JP2022501371A5 JP2022501371A5 (https=) 2022-09-13

Family

ID=69888799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021515509A Ceased JP2022501371A (ja) 2018-09-19 2019-09-19 ステロールの精製

Country Status (6)

Country Link
US (1) US20210347810A1 (https=)
EP (1) EP3852765A4 (https=)
JP (1) JP2022501371A (https=)
CA (1) CA3112878A1 (https=)
MA (1) MA53666A (https=)
WO (1) WO2020061317A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115684404B (zh) * 2022-10-27 2024-12-13 广东省科学院动物研究所 一种冬虫夏草的指纹图谱构建方法及应用
CN121487722A (zh) * 2023-04-14 2026-02-06 北京剂泰生命科技有限公司 靶向脾的脂质纳米颗粒
MA62195B1 (fr) * 2023-09-01 2025-07-31 École Supérieure Des Industries Du Textile Et De L'habillement (Esith) Composition ayant une activité antitumoral obtenues à partir de dérivés de molécules d’extrait de la plante d’alfa
WO2026029597A1 (ko) * 2024-07-31 2026-02-05 주식회사 메디치바이오 신규한 스테롤 지질 또는 이의 유도체를 함유하는 지질 나노입자 조성물
EP4700037A1 (en) * 2024-08-20 2026-02-25 Otto-von-Guericke-Universität Magdeburg Körperschaft des Öffentlichen Rechts Synthesis of isotope labeled cholesterol derivatives as diagnostic agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102978272A (zh) * 2011-09-06 2013-03-20 江南大学 一种新型植物甾醇或/和植物甾烷醇衍生物的制备方法
CN104402960A (zh) * 2014-12-16 2015-03-11 吉林农业大学 糠酸环戊烷并多氢菲酯a及其提取方法和药物用途
KR20160099417A (ko) * 2015-02-12 2016-08-22 계명대학교 산학협력단 나노 운반체 및 이를 함유하는 피부 외용제 조성물
CN106987024A (zh) * 2017-04-13 2017-07-28 东南大学 一种红外兼容微波纳米复合吸波材料及其制备方法
US20170325457A1 (en) * 2016-04-28 2017-11-16 Preceres Inc. Formulations for the delivery of active agents to insects, plants, and plant pathogens

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1002346A (en) * 1963-10-10 1965-08-25 Searle & Co Aminoalkyl esters of 3ª‰-hydroxypregn-5-en-20-one
US6645953B2 (en) * 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
WO2000052029A1 (en) * 1999-03-04 2000-09-08 Eugene Science Inc. Water-soluble sterol derivative for inhibiting cholesterol absorption and process for preparing the same
CA2762095A1 (en) * 2009-05-16 2010-11-25 Kunyuan Cui Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules
EP3318248B1 (en) * 2009-12-01 2019-04-10 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
JP6157492B2 (ja) * 2011-11-24 2017-07-05 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） ステロール誘導体の調製方法
FR3024361B1 (fr) * 2014-07-30 2017-11-24 Affichem Utilisation de derives de sterols pour traitement de la perte auditive neurosensorielle et composition correspondante

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102978272A (zh) * 2011-09-06 2013-03-20 江南大学 一种新型植物甾醇或/和植物甾烷醇衍生物的制备方法
CN104402960A (zh) * 2014-12-16 2015-03-11 吉林农业大学 糠酸环戊烷并多氢菲酯a及其提取方法和药物用途
KR20160099417A (ko) * 2015-02-12 2016-08-22 계명대학교 산학협력단 나노 운반체 및 이를 함유하는 피부 외용제 조성물
US20170325457A1 (en) * 2016-04-28 2017-11-16 Preceres Inc. Formulations for the delivery of active agents to insects, plants, and plant pathogens
CN106987024A (zh) * 2017-04-13 2017-07-28 东南大学 一种红外兼容微波纳米复合吸波材料及其制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARCHIV DER PHARMAZIE, vol. 319(7), JPN6023043818, 1986, pages 615 - 624, ISSN: 0005373822 *
JOURNAL OF THE CHINESE CHEMICAL SOCIETY, vol. 44(4), JPN6023043817, 1997, pages 395 - 399, ISSN: 0005373821 *
ＲＥＧＩＳＴＲＹ（ＳＴＮ）［ＯＮＬＩＮＥ］, JPN7024003028, 13 October 1989 (1989-10-13), pages 1 - 1, ISSN: 0005373820 *
油化学, vol. 24(8), JPN6023043819, 1975, pages 505 - 510, ISSN: 0005373823 *

Also Published As

Publication number Publication date
CA3112878A1 (en) 2020-03-26
MA53666A (fr) 2021-07-28
EP3852765A1 (en) 2021-07-28
US20210347810A1 (en) 2021-11-11
WO2020061317A1 (en) 2020-03-26
EP3852765A4 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
JP7817473B2 (ja) 治療薬の細胞内送達のための分岐状尾部脂質化合物及び組成物
CN114728886B (zh) 用于细胞内递送治疗剂的含碳酸酯的脂质化合物和组合物
CN114206827B (zh) 脂质纳米颗粒组合物
JP2022501371A (ja) ステロールの精製
JP2022501348A (ja) ステロール類似体及びその使用
CN117377653A (zh) 用于治疗剂的细胞内递送的支链尾端脂质化合物和组合物
TW202139976A (zh) 製備脂質奈米顆粒之方法
JP2022008431A (ja) 治療剤の細胞内送達のための化合物および組成物
JP2020514366A (ja) 治療剤の細胞内送達のための化合物及び組成物
CN119072464A (zh) 新型可电离脂质和脂质纳米颗粒以及其使用方法
RS63051B1 (sr) Jedinjenja i kompozicije za intracelularnu isporuku agenasa
CN118829625A (zh) 新型可电离脂质和脂质纳米颗粒以及它们的使用方法
CN116323627B (zh) 脂质化合物和脂质纳米颗粒组合物
US20260028323A1 (en) Lipid compounds and lipid nanoparticle compositions
WO2024153098A1 (zh) 脂质化合物和脂质纳米颗粒组合物
WO2024022263A1 (zh) 脂质化合物和脂质纳米颗粒组合物
WO2024199282A1 (zh) 脂质化合物和脂质纳米颗粒组合物
JP2025530781A (ja) 新規のイオン化可能な脂質および脂質ナノ粒子ならびにそれらの使用方法
WO2024109798A1 (zh) 脂质化合物和脂质纳米颗粒组合物
WO2025146125A1 (zh) 用于递送的脂质化合物和脂质纳米颗粒
CN120230759A (zh) 表达肉毒素的纳米脂质体颗粒及其应用
WO2025160127A1 (en) Ionizable lipids and compositions thereof for delivery of therapeutic agents
WO2024083172A1 (zh) 脂质化合物和脂质纳米颗粒组合物
JP2025514198A (ja) 二重機能免疫調節化合物、製剤、及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250122

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250304

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20250624